Vascular Remodeling Marks Tumors That Recur during Chronic Suppression of Angiogenesis

Molecular Cancer Research

Volumn 2, Issue 1, 2004, Pages 36-42

  Huang, Jianzhong ^a   Softer, Samuel Z ^a   Kim, Eugene S ^a   McCrudden, Kimberly W ^a   Huang, Joe ^a   New, Tamara ^a   Manley, Christina A ^a   Middlesworth, William ^a   O'Toole, Kathleen ^a   Yamashiro, Darrell J ^a   Kandel, Jessica J ^a  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPHRIN B2; PLATELET DERIVED GROWTH FACTOR B; TOPOTECAN; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; MOUSE; NEPHROBLASTOMA; NONHUMAN; NUDE MOUSE; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPHRIN-B2; FEMALE; FLUORESCEIN ANGIOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IN SITU HYBRIDIZATION; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WILMS TUMOR;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0842304140     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390: 404-407, 1997.
2. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity (In process citation). J. Clin. Invest., 105: R15-R24, 2000.
3. Howell, K., Preston, R. J., and McLoughlin, P. Chronic hypoxia causes angiogenesis in addition to remodeling in the adult rat pulmonary circulation. J. Physiol., 547: 133-145, 2003.
4. Chavez, J. C., Agani, F., Pichiule, P., and LaManna, J. C. Expression of hypoxia-inducible factor-1α in the brain of rats during chronic hypoxia. J. Appl. Physiol., 89: 1937-1942, 2000.
5. Thron, C. D., Chen, J., Leiter, J. C., and Ou, L. C. Renovascular adaptive changes in chronic hypoxic polycythemia. Kidney Int., 54: 2014-2020, 1998.
6. Berking, C., Takemoto, R., Schaider, H., Showe, L., Satyamoorthy, K., Robbins, P., and Herlyn. M. Transforming growth factor-β1 increases survival of human melanoma through stroma remodeling. Cancer Res., 61: 8306-8316, 2001.
7. Tuxhorn, J. A., Ayala, G. E., Smith, M. J., Smith, V. C., Dang, T. D., and Rowley, D. R. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res., 8: 2912-2923, 2002.
8. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal (See comments). J. Clin. Invest., 103: 159-165, 1999.
9. Faller, D. V. Endothelial cell responses to hypoxic stress. Clin. Exp. Pharmacol. Physiol., 26: 74-84, 1999.
10. Kourembanas, S., Hannan, R. L., and Faller, D. V. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J. Clin. Invest., 86: 670-674, 1990.
11. Adams, R. H., Wilkinson, G. A., Weiss, C., Diella, F., Gale, N. W., Deutsch, U., Risau, W., and Klein, R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev., 13: 295-306, 1999.
12. Oike, Y., Ito, Y., Hamada, K., Zhang, X. Q., Miyata, K., Arai, F., Inada, T., Araki, K., Nakagata, N., Takeya, M., Kisanuki, Y. Y., Yanagisawa, M., Gale, N. W., and Suda, T. Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells. Blood. 100: 1326-1333, 2002.
13. Gale, N. W., Baluk, P., Pan, L., Kwan, M., Holash, J., DeChiara, T. M., McDonald, D. M., and Yancopoulos, G. D. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev. Biol., 230: 151-160, 2001.
14. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 362: 841-844, 1993.
15. Gerber, H. P., Kowalski, J., Sherman, D., Eberhard, D. A., and Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res., 60: 6253-6258, 2000.
16. Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., Bohlen, P., and Hicklin, D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res., 59: 5209-5218, 1999.
17. Yang, J. C., Haworth, L., Steinberg, S. M., Rosenberg, S. A., and Novotny, W. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 21: 15, 2002.
18. Soffer, S. Z., Moore, J. T., Kim, E., Huang, J., Yokoi, A., Manley, C., O'Toole, K., Stolar, C., Middlesworth, W., Yamashiro, D. J., and Kandel, J. J. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J. Pediatr. Surg., 36: 1177-1181, 2001.
19. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
20. Rapisarda, A., Uranchimeg, B., Scudiero, D. A., Selby, M., Sausville, E. A., Shoemaker, R. H., and Melillo, G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res., 62: 4316-4324, 2002.
21. Soffer, S. Z., Kim, E., Moore, J. T., Huang, J., Yokoi, A., Manley, C., O'Toole, K., Middlesworth, W., Stolar, C., Yamashiro, D., and Kandel, J. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J. Pediatr. Surg., 36: 1781-1784, 2001.
22. Rowe, D. H., Huang, J., Kayton, M. L., Thompson, R., Troxel, A., O'Toole, K. M., Yamashiro, D., Stolar, C. J., and Kandel, J. J. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J. Pediatr. Surg., 35: 30-32; discussion 32-33, 2000.
23. Abramovitch, R., Dafni, H., Smouha, E., Benjamin, L. E., and Neeman, M. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res., 59: 5012-5016, 1999.
24. Korft, T., Kimmina, S., Martiny-Baron, G., and Augustin, H. G. Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J., 15: 447-457, 2001.
25. Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., and Wiegand, S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 284: 1994-1998, 1999.